梅特福林的使用与帕金森病糖尿病患者的死亡风险降低有关
Gianni Pezzoli1, Emanuele Cereda2, Daniela Calandrella1
1Parkinson Institute Milan, ASST G.Pini-CTO, via Bignami 1, Milan, Italy; Fondazione Grigioni per il Morbo di Parkinson, Milan, Italy.
Clinical nutrition ESPEN
|March 13, 2024
概括
在患有帕金森病和2型糖尿病的患者中使用甲福明并没有增加死亡风险. 这项研究表明,甲福明可能是治疗这两种疾病的有益疗法,因此需要进一步调查其疾病修饰潜力.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 临床药理学 临床药理学
背景情况:
- 帕金森病 (PD) 和2型糖尿病 (T2D) 具有共同的病理生理机制,可能会恶化PD的进展.
- 正在探索抗糖尿病疗法作为PD的潜在疾病修饰策略.
- 了解特定治疗对PD患者死亡率的影响至关重要.
研究的目的:
- 评估包括甲福明在内的抗糖尿病治疗对帕金森病和2型糖尿病患者全因死亡率的影响.
- 为了比较使用甲福明治疗的PD患者与其他口服抗糖尿病药物 (OADs) 的T2D患者之间的生存率.
主要方法:
- 采用了一个嵌套的病例控制前性研究设计.
- 包括159名新诊断的PD患者,PD发病后±2年内出现T2D,与795名非糖尿病PD患者相匹配1:5
- 患者根据包括甲福明的治疗与其他OADs的治疗进行了分层,随访直到死亡或审查.
主要成果:
- 糖尿病本身与PD患者的生存率降低无关 (HR=1.19).
- 包括甲胺的疗法没有增加死亡风险 (HR=1.06).
- 相反,接受其他OAD治疗的患者的生存率降低 (HR=1.83,P=0.034).
结论:
- 梅特福林的使用与糖尿病PD患者的死亡率增加无关.
- 甲胺是一种有希望的,具有成本效益和安全的PD疾病修饰疗法.
- 需要进一步的研究来证实甲胺对帕金森病进展的影响.
相关概念视频
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
01:23Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
01:36Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174